Subscribe to RSS
DOI: 10.1055/a-1039-1471
Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?
![](https://www.thieme-connect.de/media/hmr/201912/lookinside/thumbnails/10.1055-a-1039-1471-1.jpg)
Abstract
As the rate of obesity and the incidence of diabetes mellitus have been increasing, diabetic neuropathy has become the most common cause of peripheral neuropathy in developed countries. In addition, a variety of pathogenetically heterogeneous disorders can lead to impairment of the peripheral nervous system including amyloidosis, vitamin deficiencies, uremia and lipid disorders, alcohol abuse, autoimmune and infectious diseases as well as exposure to environmental toxins. We have noted that a combination of these disorders may aggravate the manifestations of peripheral diabetic neuropathy, an effect, which is most pronounced when metabolic and non-metabolic pathologies lead to cumulative damage. Current treatment options are limited and generally have unsatisfactory results in most patients. Therapeutic apheresis (INUSpherese®) allows the removal of metabolic, inflammatory, immunologic and environmental contributors to the disease process and may be an effective treatment option. We reviewed the developments in therapeutic apheresis for metabolic and non-metabolic peripheral neuropathy, including the current literature as well as data from our university diabetes center.
Publication History
Received: 01 October 2019
Accepted: 29 October 2019
Article published online:
11 December 2019
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 Hehir 2nd MK, Logigian EL. Infectious neuropathies. Continuum (Minneap Minn) 2014; 20: 1274-1292
- 2 Gwathmey KG, Pearson KT. Diagnosis and management of sensory polyneuropathy. BMJ 2019; 365: l1108
- 3 Watson JC, Dyck PJ. Peripheral neuropathy: A practical approach to diagnosis and symptom management. Mayo Clin Proc 2015; 90: 940-951
- 4 Katona I, Weis J. Diseases of the peripheral nerves. Handb Clin Neurol 2017; 145: 453-474
- 5 Tesfaye S, Boulton AJ, Dyck PJ. et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293
- 6 Ziemssen T, Siepmann T. The investigation of the cardiovascular and sudomotor autonomic nervous system-a review. Front Neurol 2019; 10: 53
- 7 Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-1270
- 8 Zochodne DW. The challenges of diabetic polyneuropathy: A brief update. Curr Opin Neurol 2019; 32: 66-675
- 9 Bonhof GJ, Herder C, Strom A. et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 2019; 40: 153-192
- 10 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: A 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
- 11 Vinik AI. Clinical practice. Diabetic sensory and motor neuropathy. N Engl J Med 2016; 374: 1455-1464
- 12 Amour AA, Chamba N, Kayandabila J. et al. Prevalence, patterns, and factors associated with peripheral neuropathies among diabetic patients at tertiary hospital in the Kilimanjaro Region: Descriptive cross-sectional study from North-Eastern Tanzania. Int J Endocrinol 2019; 5404781
- 13 Pai YW, Lin CH, Lin SY. et al. Reconfirmation of newly discovered risk factors of diabetic peripheral neuropathy in patients with type 2 diabetes: A case-control study. PLoS One 2019; 14: e0220175
- 14 Gokcay Canpolat A, Emral R, Keskin C. et al. Association of monocyte-to-high density lipoprotein-cholesterol ratio with peripheral neuropathy in patients with Type II diabetes mellitus. Biomark Med 2019; 13: 907-915
- 15 Zhen Q, Yao N, Chen X. et al. Total body adiposity, triglycerides, and leg fat are independent risk factors for diabetic peripheral neuropathy in chinese patients with type 2 diabetes mellitus. Endocr Pract 2019; 25: 270-278
- 16 Perez-Matos MC, Morales-Alvarez MC, Mendivil CO. Lipids: A suitable therapeutic target in diabetic neuropathy?. J Diabetes Res 2017; 2017: 6943851
- 17 Othman A, Benghozi R, Alecu I. et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?. J Clin Lipidol 2015; 9: 568-575
- 18 Abraham A, Katzberg HD, Lovblom LE. et al. Uric acid levels correlate with sensory nerve function in healthy subjects. Can J Neurol Sci 2019; 46: 337-341
- 19 Singh AK, Kumar A, Karmakar D. et al. Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med 2013; 59: 253-257
- 20 Owhin SO, Adaja TM, Fasipe OJ. et al. Prevalence of vitamin B12 deficiency among metformin-treated type 2 diabetic patients in a tertiary institution, South-South Nigeria. SAGE Open Med 2019; 7: 2050312119853433
- 21 Alharbi TJ, Tourkmani AM, Abdelhay O. et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. PLoS One 2018; 13: e0204420
- 22 Munukutla S, Pan G, Deshpande M. et al. Alcohol toxicity in diabetes and its complications: A double trouble?. Alcohol Clin Exp Res 2016; 40: 686-697
- 23 Staff NP, Windebank AJ. Peripheral neuropathy due to vitamin deficiency, toxins, and medications. Continuum (Minneap Minn) 2014; 20: 1293-1306
- 24 Pizzorno J. Is the diabetes epidemic primarily due to toxins?. Integr Med (Encinitas) 2016; 15: 8-17
- 25 Colbeth HL, Zeig-Owens R, Webber MP. et al. Post-9/11 peripheral neuropathy symptoms among world trade center-exposed firefighters and emergency medical service workers. Int J Environ Res Public Health 2019; 16: 1727
- 26 Straube R, Voit-Bak K, Gor A. et al. Lipid profiles in lyme borreliosis: a potential role for apheresis?. Horm Metab Res 2019; 51: 326-329
- 27 Julius U, Tselmin S, Fischer S. et al. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption. Atheroscler Suppl 2009; 10: 12-16
- 28 Kopprasch S, Graessler J, Bornstein SR. et al. Beyond lowering circulating LDL: Apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler Suppl 2009; 10: 34-38
- 29 Julius U, Taseva K, Fischer S. et al. Current situation of lipoprotein apheresis in Saxony. Atheroscler Suppl 2013; 14: 51-55
- 30 Feingold K, Grunfeld C, Lipoprotein Apheresis In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP. Eds Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000
- 31 Isei T, Abe M, Nakanishi T. et al. The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene. J Dermatol 2016; 43: 591-619
- 32 Weiss N. A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome. Semin Dial 2012; 25: 220-227
- 33 Rietzsch H, Panzner I, Selisko T. et al. Heparin-induced Extracorporeal LDL Precipitation (H.E.L.P) in diabetic foot syndrome - preventive and regenerative potential?. Horm Metab Res 2008; 40: 487-490
- 34 Nishimura H, Enokida H, Sakamoto T. et al. Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. J Artif Organs 2018; 21: 378-382
- 35 Buzzigoli SB, Genovesi M, Lambelet P. et al. Plasmapheresis treatment in Guillain-Barre syndrome: potential benefit over intravenous immunoglobulin. Anaesth Intensive Care 2010; 38: 387-389
- 36 Sakai Y, Otsuka T, Tsuruoka S. A case of neuromyelitis optica spectrum disorder with early successful induction of double filtration plasmapheresis. Ther Apher Dial 2014; 18: 317-318
- 37 Muhlhausen J, Kitze B, Huppke P. et al. Apheresis in treatment of acute inflammatory demyelinating disorders. Atheroscler Suppl 2015; 18: 251-256
- 38 Teng D, Tan S, Yang M. et al. A case report of hepatitis B related optic neuritis treated with plasma exchange. Medicine (Baltimore) 2019; 98: e15432
- 39 Deschamps R, Gueguen A, Parquet N. et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol 2016; 263: 883-887